reason report
price pay gx price fix lower
bottom line base bottom-up analysi potenti
damag ct gener drug price fix lawsuit
announc recent lower pt teva
point overal
believ stock current level reflect fairli conserv
interpret outcom case still remain
uncertainti around case look improv fundament
get construct name teva central lawsuit
appear appropri impact believ
despit lose market cap could still exposur
although acknowledg approach calcul
damag err side caution seem
hit estim look interest
valuat perspect rule addit lawsuit
look improv fundament get construct
appear appropri impact view
host call titl gener price fix alleg
smoke gun today pm et
medacorp specialist lawyer focus litig relat
pharmaceut medic devic pleas contact svb
leerink repres detail
teva central player ct lawsuit stock reaction appear
appropri reflect potenti damag connect
product complaint product list ct
lawsuit connect teva estim
iqvia sale question may result
alleg price fix activ estim damag
extra profit thu believ market cap lost teva
week follow releas ct lawsuit
minut report appropri part lower pt
reflect estim extra profit damag
levothyroxin would largest sourc potenti
damag although acknowledg assumpt
made frame potenti damag like err side caution
product ct lawsuit connect repres
iqvia sale may result
alleg price fix activ damag extra profit
could assess come levothyroxin
compani inform svb leerink llc research
pleas refer page import disclosur price chart analyst certif
complet may edt distribut may edt rx trend deriv im health
iqvia sale question start januari price
increas call ct lawsuit stock lost market
cap notabl less estim believ
estim could conserv inher limit inform
privi moment calcul design price
increas mention complaint inappropri also
increas occur post within scope
complaint howev deem price inflat
legitim would lower estim potenti damag mylan
in-lin stock reaction
exampl highlight inher uncertainti determin potenti
damag compani may pay believ
subject signific negoti said conserv lower
pt reflect estim damag
agre stock reaction amneal appear outsiz
vs product identifi complaint believ
stori ultim keep us sidelin
product ct lawsuit connect amneal estim
iqvia sale question may
result alleg price fix activ damag
extra profit could assess meaning lower
reduct market cap seen stock believ
could due two potenti reason first amneal may
higher risk product eventu come investig given
name lawsuit fact estim
product market lawsuit amneal was/i
mention defend estim includ product
would increas damag second amneal deriv
sale levothyroxin come scrutini case
could present overhang stock overal lower
pt slightli reflect estim extra profit
damag although stock current trade remain market
perform still see risk manag hit guidanc
look visibl new product launch
acknowledg mani unknown exist term
wide scope price fix could
potenti penalti settlement amount ultim
determin level detail present complaint
strike attempt quantifi impact reflect
valuat util iqvia data detail outlin ct
complaint estim potenti damag amount compani
product-by-product basi base natur alleg
price fix action price increas price mainten use
iqvia estim extra sale gener translat
profit potenti trebl damag bodi note
detail methodolog estim total sale
question extra sale gain alleg price fix
profit damag amount list individu
product compani investig
price pay gx price fix lower teva pt
ct lawsuit drug collus give us window scope depth
on-going investig may domino yet fall
could product
broader scope investig still
on-going one compani
type
could higher-level execut
name defend
forth state
doj get involv
appear detail certain
text/phon log
power weight evid
potenti defens defend
complaint detail time
basi use determin excess
alleg collus began
compani involv type
svb leerink research us district court connecticut gener drug anti-trust lawsuit
far would damag calcul
attorney side come
teva seem expos amneal seem
svbl estimate
mix type
product
mention
complaint
svb leerink research us district court connecticut gener drug anti-trust lawsuit iqvia pricerx
possibl come beyond current complaint
compani could implic
latest complaint focus teva behavior
compani involv given
product mention complaint
investig could still on-going
specif compani network behavior
second two complaint file
topic first file
statut limit may driven order
investig
could
tip iceberg
case typic initi
depart justic doj level
type evid suggest doj involv
may also result crimin charg
sever possibl
compani execut directli involv
wrongdo could get name defend
rule public compani
defend like also put togeth defens strategi mitig
attempt estim much addit sale gener alleg collus activ
acknowledg assumpt would heavili scrutin debat part
potenti defens argument could along follow line
 specif market dynam slow pace fda anda approv disrupt suppli certain
manufactur allow compani market realiz better price
 time-frame benefit compani limit market dynam didnt stay
complaint focus primarili period begin juli januari one topic debat
could even compani stop collud period onward sale benefit
bump result collus see exampl next slide
 commun employe compet compani could mani reason
commun may attempt competit intellig rather explicit act collus
wise good term competitor one day employe may need switch job
sever unknown remain around breadth timelin around
case attempt estim impact base avail inform
methodolog use calcul potenti damag
scope
use complaint guid determin scope product
compani
limit scope calcul compani coverag
compani cover implic product complaint
 teva
 mylan
 endo
 amneal
compani mention complaint includ
compani identifi product mention complaint time point anti-
competit conduct allegedli began product subject complaint one compani
particip market mention complaint assum compani involv
collus relat product
use iqvia identifi amount sale gener time point today
svb leerink research us district court connecticut gener drug anti-trust lawsuit medacorp specialist feedback
categor collus product type anti-
competit conduct alleg complaint
identifi product subject
particular gener drug
estim excess sale calcul
differ sale realiz sale
would occur volum sold
price prior increas
type anti-
identifi product subject
collus maintain price despit chang
competit landscap entri competitor
estim excess sale
differ sale realiz sale
would typic occur base number
design product unknown
complaint provid suffici detail us
make assess type anti-competit
estim excess sale use similar
methodolog price mainten situat
assum uniform discount believ
typic one addit entrant market
svb leerink research us district court connecticut gener drug anti-trust lawsuit
estim much sale gener alleg anti-
competit conduct deriv potenti damag amount
price/ rx product
date
report
product-by-product basi
haircut iqvia captur rate
report sale
probabl adjust product
base level evid
detail complaint
product extens
detail complaint describ
product littl
accompani detail and/or identifi
potenti correl price increas
base pricerx data
product mention
complaint without detail
identifi obviou correl price
increas base pricerx data
assum oper profit
multipli oper profit
reflect trebl damag
expect case per
feedback medacorp
svb leerink research us district court connecticut gener drug anti-trust lawsuit medacorp specialist feedback
exampl price increas clomipramin
background complaint alleg sandoz taro conspir follow other price increas
may taro rais price certain formul
defend taro sandoz commun one anoth date price increas
compani agre poach other custom follow price increas one exampl cite sandoz
declin bid taro custom taro rais price
rais price may per unit cost taro sandoz follow suit juli
svbl framework estim extra sale gain clomipramin market
excess price price
price per may
potenti damag relat
end
price per trx
assum without
collus drive price higher
price/rx would continu
per date
time-frame begin
may rais
iqvia
captur rate haircut would
assum prescript
assum oper profit
volum sold today
continu benefit
margin excess profit
would
probabl adjust
total iqvia report sale
time-frame
sale would
without price increas
damag would
amount
svb leerink research us district court connecticut gener drug anti-trust lawsuit iqvia pricerx
exampl price mainten fenofibr
background complaint alleg teva lupin conspir alloc market upon mylan gx entri
end teva gener fenofibr market lupin
plan launch gener defend teva lupin regular contact
phone share inform launch plan market share alloc
logic alloc larg enough custom would need compet price teva
conced econdisc largest custom largest
svbl framework estim extra sale gain teva fenofibr market
assum prior mylan
potenti damag relat
entri june price
player
time-frame begin
june enter
market
iqvia
captur rate haircut would
assum without
assum prescript
assum oper profit
collus maintain price
price/rx would declin
reflect entri
volum sold today
continu benefit price
margin excess profit
would
probabl adjust
total iqvia report sale
time-frame
sale would
without price mainten
damag would
amount
svb leerink research us district court connecticut gener drug anti-trust lawsuit iqvia pricerx
base feedback medacorp specialist estim damag
teva neglig
question
svbl estimate
trebl
impact leverag
estim impact leverag base
compani expect ebitda although
acknowledg potenti cash outflow would like
take place year today
leverag
use mid-point ebitda guidanc
addit debt increas
leverag
leverag
use mid-point ebitda guidanc
addit debt increas
leverag
leverag
use mid-point ebitda guidanc
addit debt increas
leverag
compani end net debt
leverag
use mid-point ebitda guidanc
addit debt increas
leverag
note includ estim individu product appendix
svb leerink research us district court connecticut gener drug anti-trust lawsuit iqvia pricerx
lower valuat compani base
estim profit damag stem complaint
examin disconnect estim stock reaction
 believ taken conserv view estim excess sale might explain lower
stock reaction could simpli stock taken signific hit alreadi ytd
 calcul damag assum price increas follow first price increas due collus
achiev anti-competit activ defend may argu otherwis
 damag calcul come levothyroxin
 stock move appear overreact given compani implic
 valuat look attract current level remain sidelin continu see risk
compani guidanc also see limit near term catalyst new launch
believ analysi conserv estim extra sale like result
outsiz impact estim due exposur levo
complaint specif call three price increas discuss
potenti price collus yet iqvia impli price per continu increas
estim excess sale assum price increas level due collus
sinc complaint cover activ possibl evid come
case assumpt would correct
altern may also abl establish increas occur legitim reason
revis calcul assum price appreci legitim would reduc
estim total extra profit damag
 estim assum price/trx
per orang line yield
extra profit damag levothyroxin
 revis calcul indic
price/trx per grey line would
reduc extra profit damag
levo
 overal chang would reduc
estim extra profit damag
still impli market cap
declin in-lin
stock reaction
consist across
compani lower valuat
full estim
price/trx mylan gx levothyroxin scenario
increas mention
complaint
svb leerink research us district court connecticut gener drug anti-trust lawsuit iqvia pricerx
stock reaction amneal outsiz consid product mention
complaint remain sidelin
amneal lost market cap week follow releas complaint
 howev product mention connect amneal
 total iqvia sale gener time alleg collus year sale
calcul extra profit damag product
see two primari reason larg disconnect stock reaction potenti damag
amneal could potenti implic product besid recent compliant
estim addit product list market amneal previous
current amneal identifi defend alleg price fix activ product
point reason suggest amneal wrongdo market includ
product would increas extra profit damag calcul amneal
although amneal specif implic levo product includ complaint
largest revenu contributor compani estim
amneal own levothyroxin previous market lannett amneal involv alleg
price collus levothyroxin outlin previou slide price today may reflect benefit
collus
given signific levo amneal revenu level on-going scrutini around product
price increas histori would expect contribut overhang stock
base strictli fact hand believ stock overreact remain
sidelin amneal reason highlight previous
 believ manag risk miss guidanc target model ep vs
ebitda vs
 lack visibl new product launch meaning contributor next month
 see notabl near-term catalyst
svb leerink research us district court connecticut gener drug anti-trust lawsuit iqvia
total sale question
svbl estim extra sale
svbl estim extra profit damag
total sale question
svbl estim extra sale
svbl estim extra profit damag
total sale question
svbl estim extra sale
svbl estim extra profit damag
svb leerink research us district court connecticut gener drug anti-trust lawsuit iqvia pricerx
rate amneal mp contribut new product launch expect
furthermor see gross margin take step annual
levothyroxin margin profil improv long run cost save kick
final perform recent complex gener launch suggest go forward
opportun may larg assum see uncertainti long term
larg opportun could
use weight averag ev/ebitda multipl ebitda
deriv pt valuat includ cash outflow base estim
potenti damag relat on-going gener price fix lawsuit
delay new product launch addit competit entrant key product franchis
gx vagifem voltaren gel aggrenox levothyroxin greater-than-expect cost save
realiz earlier-than-expect approv gx copaxon less-than-expect competit
landscap gx nuvar
assign endo market perform rate xiaflex steril inject continu perform
well see continu headwind us gener potenti gener competit
vasostrict adrenalin overal model top-lin compound-annual-growth-rate see gross
margin near-to-medium term unlik recov level
oper margin rel steadi low rang believ signific
invest need commerci collagenas clostridium histolyticum cch result
declin low rang final see posit catalyst potenti
headlin risk on-going opioid litig remain overhang stock
price target base ebitda ev/ebitda
multipl valuat incorpor addit payment relat mesh
product liabil includ potenti payment relat on-going opioid litig
valuat also includ cash outflow base estim potenti
damag relat on-going gener price fix lawsuit
delay gener competit vasostrict adrenalin opioid litig liabil larger
expect delay time new gx launch lower-than-expect growth steril
inject higher-than-expect growth xiaflex cellulit opportun may larg
anticip
place outperform rate share base strong pipelin biosimilar
durabl ou busi growth off-set continu us base busi
gener eros support revenu growth potenti near-term
upsid consensu number limit competit copaxon advair though
difficult high visibl insulin/biosimilar growth driver
could expand multipl rel peer strong balanc sheet allow
share buy-back smaller bolt-on acquisit expand geograph and/or therapeut
use weight averag ev/ebitda multipl ebitda deriv
price target per share valuat includ cash outflow base
estim potenti damag relat on-going gener price fix lawsuit
gener advair opportun may smaller estim commerci uptak
biosimilar may take longer anticip growth ou market may slower
expect market penetr gener copaxon may improv biosimilar neulasta ramp
may slower estim remedi morgantown facil may take longer
allevi reach lower capac current estim
attribut neutral outlook due five main factor brand copaxon start
see increment eros new gener entrant austedo build strong perform
proair eros gener albuterol inhal like signific impact year
ajovi trx continu ramp sale contribut remain nebul cost
may trend much manag initi guidanc still see risk
consensu number believ matter time meaning gener
competit hit copaxon proair could still downsid addit gener
still struggl see growth us gener believ manag done good job
stabil busi build block place busi grow start
rate teva market perform price target
price target base ebitda ev/ebitda multipl
line gx peer group teva lupin hik rdi ev/ebitda
multipl valuat includ cash outflow base estim potenti
damag relat on-going gener price fix lawsuit
continu delay new gener opportun slower-than-anticip ramp ajovi could
result teva trade lower price target addit delay gener competit
copaxon proair along faster growth austedo could result teva trade
brand
type event
event trial detail
date known
up/down
expect
file bla amneal partner adello
file bla amneal partner
svb leerink llc equiti research compani file
number except per share data
net debt ebitda ratio
number except per share data
budesonid pulmicort respul -- teva
number except per share data
copaxon gener alreadi market pend approv
copaxon gener alreadi market pend approv
gleevec gener alreadi market pend approv
seroquel xr gener alreadi market pend approv
lialda launch jan zydu day exclus expir
canasa assum ftf day exclus pend approv
exelon patch gener alreadi market pend approv
nuvar assum mid-year
faslodex litig progress assum settlement ftf sandoz pend approv
norvir assum patent expir jan pend approv
saphri filer lost patent pend approv
truvada assum emtricitabin patent key pend approv
amitiza assum settlement month ftf pend approv
sensipar case progress pend approv
vimpat lost patent expir pend approv
toviaz filer lost patent expir tent approv
velcad filer lost patent expir pend approv
alimta filer lost patent pend approv
vyvans lost feb patent tent approv
xyrem assum launch day hikma pend approv
onglyza franchis lost jul patent pend approv
number except per share data
sale
number except per share data
prepaid expens current
accru profit share royalti
liabil held sale
current portion ltd
number except per share data
adjust reconcil ni net cash oper
tax expens stock option rsa
accru profit share royalti expens net payment
reserv ture receiv
sale asset
loss extinguish debt
net chang fair valu deriv
recognit defer revenu
chang fair valu conting consider
decreas increas work capit
payment busi acquisit
purchas properti plant equip capital-expenditure
payment licens agreement
invest cash surrend valu insur
proce repay tolmar loan
proce sale intang asset
maturities/purchas short-term invest
net invest
payment defer financ fee
purchas bond hedg deriv asset
proce sale warrant
tax benefit stock option rsa
proce exercis stock option espp
net financ
effect exchang rate chang cash/ cash equival
net chang equival
brand
type event
event trial detail
date known
up/down
expect
emerg treatment allerg
litig trial begin
start first us district court trial
visibl opioid litig
oklahoma case due start may
litig trial begin
svb leerink llc equiti research compani file
number except per share data
net debt ebitda ratio
number except per share data
flat singl digit growth
number except per share data
vasostrict assum gener
adrenalin inject assum gener
steril inject previous new launch alt dosag
total steril inject previous new launch alt dosag
high-singl low-doubl digit
number except per share data
concerta assum get approv mid
ftf/ftm key pipelin
afinitor assum launch time-frame tent approv
zortress assum launch time-frame pend approv
ciprodex date certain entri pend approv
samsca assum entri patent expiri pend approv
zomig assum entri may patent expiri pend approv
onglyza assum entri comp patent expir pend approv
xyrem assum launch day hikma pend approv
dexil assum settlement patent expir approv
ftf/ftm key pipelin sub-tot
number except per share data
total litha somar
number except per share data
restrict cash cash equival
prepaid expens current asset
asset held sale
account payabl accru expens
current portion legal settlement
current portion ltd
liabilit held sale
number except per share data
adjust reconcil ni net cash oper
amort debt issuanc cost discount
provis bad debt
chang fair valu conting consider
loss extinguish debt
sale busi asset
decreas increas work capit
purchas properti plant equip capital-expenditure
acquisit businesses/asset net cash acquir
patent acquisit cost licens fee
proceed sale busi
increas restrict cash cash equival
net invest
borrow repay revolv credit/oth net
payment conting consider
tax benefit share award
payment tax withhold restrict share
exercis option
issuanc ordinari share
net financ
effect exchang rate chang cash/ cash equival
net chang equival
brand
type event
event trial detail
date known
up/down
expect
outcom strateg review
svb leerink llc equiti research compani file
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
advair assum get approv
letairi approv end march
ulor settlement june tent approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
januvia franchis assum compound patent tent approv
treanda assum launch end bendeka ode dec
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
ogivri biosim herceptin launch
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
brand
type event
event trial detail
date known
up/down
expect
safeti data on-going
result phase
visibl opioid litig
oklahoma case due start may
svb leerink llc equiti research compani file
number except per share data
share assoc co
net debt ebitda ratio
number except per share data
number except per share data
disclos ftf notabl pipelin
restasi patent invalid await appeal assum launch pend approv
letairi approv end march
renvela assum approv pend approv
noxafil drt assum compound patent expir jul hold pend approv
nuvar appeal state patent valid pend approv
zubsolv sept patent upheld court pend approv
latuda lost jan patent tent approv
rozerem undisclos settlement assum jul compound expiri approv
zyclara settlement jul pend approv
vigamox assum month patent expiri approv
number except per share data
abraxan ode exclus pend approv
absorica settlement dec pend approv
silenor settlement jan exclus approv
tarceva undisclos settlement assum may expiri polymorph patent pend approv
diclegi assum month patent expiri approv
atripla/truvada undisclos settlemnet assum last patent emtricitabin expir gate approv
rayo settlement approv
xopenex hfa assum month patent expiri pend approv
onglyza franchis patent upheld court pend approv
disclos ftf notabl pipelin sub-tot
number except per share data
number except per share data
number except per share data
number except per share data
asset held sale
sale reserv allow
liabil held sale
tax long-term liabil
senior note loan
number except per share data
adjust reconcil ni net cash oper
impair long-liv asset
net gain loss sale long-liv assets/invest
translat adjust due venezuela devalu
research develop process
impair equiti invest net
decreas increas work capit
sale purchas busi net cash acquir
proce sale long-liv asset invest
purchas properti plant equip capital-expenditure
purchas invest asset
net invest
dividend paid ordinari share
proce issuance/ purchas ordinari share net
proce issuanc prefer share net
dividend paid prefer share
dividend paid non-control interest
proce exercis option employe
purchas treasuri shares/ ordinari share
net financ
translat adjust cash cash equival
net chang equival
